Antigen binding protein targeting cd39 and use thereof
AssigneeOricell Therapeutics Co., Ltd.
InventorsXiaopei LI, Xiaowen HE, Qi DENG, Xianyang LI, Huajing WANG, Yuchen ZHANG
Life of this patent
Estimating the term…
Abstract
An antibody or an antigen binding fragment thereof, which can specifically bind to a CD39 protein. Further provided is the use of the antibody or the antigen binding fragment thereof in the preparation of a drug for preventing and/or treating diseases.
Claims40
An antibody or an antigen-binding fragment thereof, which can specifically bind to a CD39 protein, comprising an HCDR1, an HCDR2, and an HCDR3, wherein said HCDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO:
- 1, SEQ ID NO:
- 53, and SEQ ID NO:
- 22, or wherein said HCDR1 comprises an amino acid sequence as set forth in any one of SEQ ID NO:
- 1, SEQ ID NO:
- 9, SEQ ID NO:
- 17, and SEQ ID NO:
- 22;
- said HCDR2 comprises an amino acid sequence as set forth in any one of SEQ ID NO:
- 2, SEQ ID NO:
- 10, SEQ ID NO:
- 23, and SEQ ID NO:
- 28;
- and said HCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO:
- 3, SEQ ID NO:
- 54, and SEQ ID NO:
- 55, or wherein said HCDR3 comprises an amino acid sequence as set forth in any one of SEQ ID NO:
- 3, SEQ ID NO:
- 11, SEQ ID NO:
- 18, SEQ ID NO:
- 24, SEQ ID NO:
- 29, and SEQ ID NO:
- 33.
2-7. (canceled)
10-16. (canceled)
(canceled)
21-25. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
38-40. (canceled)
42-45. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
53-55. (canceled)
58-62. (canceled)
64-67. (canceled)
69-71. (canceled)
Dependencies are inferred from the claim text.